Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Nuclear Factor kappa B (NF-κB) pathway is frequently overexpressed in non-small cell lung cancer (NSCLC), correlating with poor prognosis and high mortality.
• Silencing key NF-κB subunits (p50 and p65) in NSCLC cells significantly reduces cell viability and downregulates crucial anti-apoptotic proteins like survivin and Mcl1.

Purpose of the Study:

• To investigate the effects of the survivin suppressant YM155 and its analog AB1 on NSCLC cell growth and NF-κB signaling.
• To elucidate the mechanism by which these compounds exert their anti-cancer effects, focusing on NF-κB pathway modulation and apoptosis induction.

Main Methods:

• Cell viability assays were performed on NSCLC H1299 cell lines treated with YM155 and AB1.
• Western blotting was used to assess the expression levels of NF-κB pathway proteins and apoptosis-related proteins.
• Luciferase reporter assays in HEK293 cells were conducted to evaluate the impact of compounds on NF-κB transcriptional activity.
• Analysis of NF-κB subunit phosphorylation and nuclear translocation was performed.

Main Results:

• YM155 and AB1 demonstrated potent growth arrest in H1299 cells at nanomolar concentrations.
• Both compounds induced apoptosis and dose-dependently suppressed survivin, Mcl1, Bcl-2, and Bcl-xl.
• YM155 and AB1 did not alter the expression of IκBα, p65, or p50, nor did they impede nuclear translocation of NF-κB subunits.
• Crucially, these compounds suppressed the phosphorylation of the p50 subunit at Ser337, inhibiting NF-κB dimer binding to DNA and attenuating NF-κB transcriptional activity.

Conclusions:

• YM155 and AB1 exhibit potent apoptogenic and cell-killing properties in NSCLC cells, likely through the "silencing" of the NF-κB pathway.
• The compounds' mechanism involves the inhibition of p50 phosphorylation at Ser337, which impairs NF-κB DNA binding and transcriptional activity.
• These findings highlight a novel mechanism of action for functionalized dioxonaphthoimidazoliums, suggesting their potential as therapeutic agents for NSCLC.